NTCC?Karpas-620 cell line is a human cell line used in oncology research, derived from the peripheral blood of a 77-year-old female patient with IgG kappa plasma cell leukemia in 1987. Plasma cell leukemia is a rare and aggressive form of multiple myeloma.

Key Characteristics

• Origin: The cells were established at the University of Cambridge from a patient's peripheral blood. They are classified as a lymphoid cell line, specifically a plasma cell myeloma type.

• Morphology: The cells grow in suspension and have the ultrastructural appearance of plasma cells, which includes abundant rough endoplasmic reticulum.

• Genetic Markers:

  • They secrete kappa light chains and are positive for surface antigens HLA DR and CD37. They are negative for CD1, CD3, CD4, and CD8.

  • The cells have a hypotetraploid karyotype and complex chromosomal aberrations, including translocations involving chromosomes 1, 11, and 14.

  • They express high levels of Cyclin D1 (CCND1) and have chromosomal abnormalities involving the c-myc locus.

Research Applications

The Karpas-620 cell line is a valuable tool for studying plasma cell leukemia and multiple myeloma, particularly for understanding the genetic and biological basis of these diseases. Its main applications include:

• Oncology Research: It serves as a model to study the progression and genetic makeup of plasma cell malignancies.

• Drug Sensitivity Screening: The cell line is used to test the effectiveness of new therapies, including chemotherapy drugs and targeted agents. For example, it has shown sensitivity to BCL-2 inhibitors like Venetoclax.

• Genetic Studies: The complex chromosomal translocations and gene expression patterns in Karpas-620 make it an important model for investigating the molecular pathways that drive these cancers.

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com

Karpas-620 細(xì)胞系是一種用于腫瘤學(xué)研究的人類細(xì)胞系，于1987年從一名77歲患有 IgG kappa 漿細(xì)胞白血病的女性患者的外周血中分離得到。漿細(xì)胞白血病是一種罕見且侵襲性強的多發(fā)性骨髓瘤。

主要特點

• 來源: 該細(xì)胞系在劍橋大學(xué)從患者的外周血中建立。它被歸類為淋巴樣細(xì)胞系，具體來說是漿細(xì)胞骨髓瘤類型。

• 形態(tài): 這些細(xì)胞在懸浮培養(yǎng)中生長，具有漿細(xì)胞的超微結(jié)構(gòu)外觀，包括豐富的粗面內(nèi)質(zhì)網(wǎng)。

• 遺傳標(biāo)記:

  • 它們分泌 kappa 輕鏈，并且表面抗原 HLA DR 和 CD37 呈陽性。而 CD1、CD3、CD4 和 CD8 呈陰性。

  • 細(xì)胞具有亞四倍體核型和復(fù)雜的染色體畸變，包括涉及1號、11號和14號染色體的易位。

  • 它們表達(dá)高水平的 Cyclin D1 (CCND1)，并且具有涉及 c-myc 基因座的染色體異常。

研究應(yīng)用

Karpas-620 細(xì)胞系是研究漿細(xì)胞白血病和多發(fā)性骨髓瘤的寶貴工具，尤其有助于理解這些疾病的遺傳和生物學(xué)基礎(chǔ)。其主要應(yīng)用包括：

• 腫瘤學(xué)研究: 它可作為模型來研究漿細(xì)胞惡性腫瘤的進(jìn)展和遺傳構(gòu)成。

• 藥物敏感性篩選: 該細(xì)胞系用于測試新療法（包括化療藥物和靶向藥物）的有效性。例如，它已顯示出對 BCL-2 抑制劑（如 Venetoclax）的敏感性。

• 遺傳學(xué)研究: Karpas-620 復(fù)雜的染色體易位和基因表達(dá)模式使其成為研究驅(qū)動這些癌癥的分子通路的重要模型。

BioVector NTCC質(zhì)粒載體菌種細(xì)胞蛋白抗體基因保藏中心

BioVector NTCC Inc.

TEL: 400-800-2947, 189-0126-8599

E-mail: [email protected]

http://www.nedfriskphoto.com